RedHill Biopharma Secures $10M Equity Line
Ticker: RDHL · Form: 6-K · Filed: Dec 23, 2025 · CIK: 1553846
| Field | Detail |
|---|---|
| Company | Redhill Biopharma Ltd. (RDHL) |
| Form Type | 6-K |
| Filed Date | Dec 23, 2025 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $25 million, $1.0235, $1 million, $25,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financing, equity-line, capital-raise
TL;DR
RedHill just inked a $10M equity deal with YA II PN, Ltd. for potential share sales over 3 years.
AI Summary
On December 19, 2025, RedHill Biopharma Ltd. entered into a Standby Equity Purchase Agreement (SEPA) with YA II PN, Ltd. This agreement allows RedHill Biopharma to sell up to $10 million of its ordinary shares to the investor over a period of 36 months, subject to certain conditions and limitations.
Why It Matters
This equity line provides RedHill Biopharma with potential access to capital, which can be crucial for funding ongoing research, development, and commercialization efforts for its pharmaceutical products.
Risk Assessment
Risk Level: medium — Standby equity agreements can dilute existing shareholders and may indicate the company needs capital, potentially signaling financial pressure.
Key Numbers
- $10 million — Standby Equity Purchase Facility (Maximum potential capital infusion over 36 months)
- 36 months — Agreement Duration (Period over which RedHill Biopharma can sell shares)
Key Players & Entities
- RedHill Biopharma Ltd. (company) — Registrant and party to the agreement
- YA II PN, Ltd. (company) — Investor in the Standby Equity Purchase Agreement
- December 19, 2025 (date) — Effective date of the Standby Equity Purchase Agreement
- $10 million (dollar_amount) — Maximum amount of ordinary shares the company can sell
FAQ
What is the purpose of the Standby Equity Purchase Agreement?
The SEPA allows RedHill Biopharma to sell up to $10 million of its ordinary shares to YA II PN, Ltd. over 36 months, providing potential access to capital.
Who is the investor in this agreement?
The investor is YA II PN, Ltd., an exempt limited company from the Cayman Islands.
When did the agreement become effective?
The Standby Equity Purchase Agreement became effective on December 19, 2025.
What is the maximum amount RedHill Biopharma can raise through this agreement?
RedHill Biopharma can sell up to $10 million of its ordinary shares under the terms of the SEPA.
What is the duration of the Standby Equity Purchase Agreement?
The agreement is in effect for a period of 36 months from the Effective Date.
Filing Stats: 1,302 words · 5 min read · ~4 pages · Grade level 11.9 · Accepted 2025-12-23 07:00:39
Key Financial Figures
- $25 million — "Advance") an aggregate amount of up to $25 million (the "Commitment Amount") of American D
- $1.0235 — Equity Shares") at a price per ADSs of $1.0235 and a pre-funded warrant (the "Pre-Fund
- $1 million — vestor, for aggregate gross proceeds of $1 million. The closing of the sale of the Initial
- $25,000 — the Investor in an aggregate amount of $25,000. The Company may terminate the SEPA at
Filing Documents
- zk2534128.htm (6-K) — 20KB
- exhibit_99-1.htm (EX-99.1) — 252KB
- exhibit_99-2.htm (EX-99.2) — 109KB
- 0001178913-25-004101.txt ( ) — 382KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. REDHILL BIOPHARMA LTD. (the "Registrant") Date: December 23, 2025 By: /s/ Dror Ben-Asher Name: Dror Ben-Asher Title: Chief Executive Officer